HIV TAT-associated sensory neuropathy and the contribution of toll-like receptor pathway

Active Grant Awarded

Award ID
RF1NS132674
Recipient
Awarding agency
Obligated
$710,000

Award facts

Assistance listing
93.310 Trans-NIH Research Support
Completion date 10% complete
Place of performance
Biddeford, ME, USA

Award details come from USAspending.gov.

About this award

The National Institute of Neurological Disorders and Stroke, within the Department of Health and Human Services' National Institutes of Health, awarded $710,000 to the University of New England on Sep 8, 2026, under Grant RF1NS132674 and Assistance Listing 93.310, Trans-NIH Research Support. The grant funds research into the mechanisms of HIV TAT-associated sensory neuropathy and the contribution of the toll-like receptor (TLR) pathway. The recipient will use bioinformatic tools to identify FDA-approved drugs that have no significant interactions with existing antiretroviral drugs and that can reverse TAT-induced changes in the TLR pathway, then test those drugs in vivo for treating TAT-associated sensory neuropathy. The project hypothesizes that TLR signaling is involved in the development of this neuropathy. The period of performance runs to an ultimate completion date of Aug 31, 2028. The place of performance is Biddeford, Maine. The source identifies no sub-recipients on this award.

Description

Abstract
Peripheral neuropathies are the most frequent neurological complications associated with HIV, within which HIV sensory neuropathy (HIV-SN) is the most common form, affecting nearly half of HIV/aids patients with the prevalence ranging from 1.2 - 69.4%. HIV-SN frequently manifests with hard-to-manage pain and is often under-diagnosed and/or under-treated, yet, the large variation in prevalence does not allow for detection of significant differences in prevalence between haart-exposed VS. Haart-non-exposed individuals. There is no specific FDA-approved treatment for HIV-SN. TAT, trans-activator of transcription, a regulatory protein among the first proteins expressed following HIV infection, is a key activator of HIV transcription and can affect both HIV infected cells and non-infected neighboring cells via its secretion by infected cells. Although human studies are lacking, recent animal studies using two models of doxycycline-inducible HIV-1 TAT transgenic (ITAT) mice from our lab and others provided convincing evidence that HIV TAT contributes to the development of HIV-SN. Therefore, in this proposal, we will further investigate the underlying mechanisms of TAT-associated SN. Our preliminary study identified potential regulation of TAT of toll-like receptor (TLR) signaling pathway. Given the widely accepted involvement of TLR pathway in neuropathic pain and surprising lack of studies exploring the role of TLR pathway in HIV-SN, we will focus on TLR pathway in TAT-associated SN in this study. We will take advantage of bioinformatic tools to identify FDA-approved drugs without significant interactions with existing antiretroviral drugs that could potentially reverse TAT-induced changes in TLR pathway, and then test their effectiveness in treating TAT-associated SN in vivo. Altogether, we hypothesize that TLR signaling pathway is involved in the development of HIV-TAT-associated SN and IT is possible to identify potential treatment for HIV-SN by examining existing drugs via a combined bioinformatics and pre-clinical model approach. This will be tested through 2 specific aims. Aim 1 will determine the contribution of tollip (a key regulator of TLR pathway)-regulated TLR pathways in HIV TAT-associated SN using genetically modified animal models in combination with behavioral and physiological tests. Aim 2 will identify potential drugs for HIV-SN by targeting TLR pathway via a combined bioinformatics and pre-clinical model approach. If successful, we will fill in the knowledge gaps regarding TAT-associated SN and tlrs' role in HIV-SN. Our comprehensive combination drug discovery strategy will help identify potential drugs for HIV-SN, which can be further tested in other animal models before clinical assessment. Throughout the process, we will prioritize drug candidates that are mechanistically-sound, and potentially easily accessible to all patients.

Quick answers

Who received award RF1NS132674?

RF1NS132674 was awarded to University Of New England by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 8, 2026.

How much is award RF1NS132674 worth?

$710,000 has been obligated on RF1NS132674.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award